Journal
CLINICAL CANCER RESEARCH
Volume 19, Issue 9, Pages 2393-2405Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-12-2170
Keywords
-
Categories
Funding
- Chief Scientists Office Scotland [CZB/4/748]
- Tenovus-Scotland
- Kay Kendall Leukaemia Fund [KKL501]
- Cancerpole Grand-Ouest
- Association pour la Recherche sur le Cancer [ARC-1092]
- Ligue Nationale contre le Cancer (Comite Grand-Ouest)
- MRC
- MRC [G0701354] Funding Source: UKRI
- Chief Scientist Office [CZB/4/748] Funding Source: researchfish
- Medical Research Council [G0701354] Funding Source: researchfish
Ask authors/readers for more resources
Purpose: Chronic lymphocytic leukemia (CLL) is currently incurable with standard chemotherapeutic agents, highlighting the need for novel therapies. Overcoming proliferative and cytoprotective signals generated within the microenvironment of lymphoid organs is essential for limiting CLL progression and ultimately developing a cure. Experimental Design: We assessed the potency of cyclin-dependent kinase (CDK) inhibitor CR8, a roscovitine analog, to induce apoptosis in primary CLL from distinct prognostic subsets using flow cytometry-based assays. CLL cells were cultured in in vitro prosurvival and proproliferative conditions to mimic microenvironmental signals in the lymphoid organs, to elucidate the mechanism of action of CR8 in quiescent and proliferating CLL cells using flowcytometry, Western blotting, and quantitative real-time PCR. Results: CR8 was 100-fold more potent at inducing apoptosis in primary CLL cells than roscovitine, both in isolated culture and stromal-coculture conditions. Importantly, CR8 induced apoptosis in CD40-ligated CLL cells and preferentially targeted actively proliferating cells within these cultures. CR8 treatment induced downregulation of the antiapoptotic proteins Mcl-1 and XIAP, through inhibition of RNA polymerase II, and inhibition of NF-kappa B signaling at the transcriptional level and through inhibition of the inhibitor of I kappa B kinase (IKK) complex, resulting in stabilization of I kappa B alpha expression. Conclusions: CR8 is a potent CDK inhibitor that subverts pivotal prosurvival and proproliferative signals present in the tumor microenvironment of CLL patient lymphoid organs. Our data support the clinical development of selective CDK inhibitors as novel therapies for CLL. (C) 2013 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available